1-[2-[[2-[[4-(4-fluorophenyl)phenyl]methyl]-1-oxo-3,4-dihydroisoquinolin-6-yl]oxy]ethyl]-1-hydroxyurea | 147497-10-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 1-[2-[[2-[[4-(4-fluorophenyl)phenyl]methyl]-1-oxo-3,4-dihydroisoquinolin-6-yl]oxy]ethyl]-1-hydroxyurea
• 英文别名: 2-(4'-fluoro-4-biphenylylmethyl)-6-[2-(N-aminocarbonyl-N-hydroxyamino)-ethoxy]-1-oxo-1,2,3,4-tetrahydroisoquinoline
• CAS: 147497-10-7
• 化学式: C₂₅H₂₄FN₃O₄
• 分子量: 449.5
• InChiKey: QFDRKYCYRMSXMS-UHFFFAOYSA-N

物化性质

• 沸点：
  714.8±70.0 °C(Predicted)
• 密度：
  1.344±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  96.1
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-[2-[[2-[[4-(4-fluorophenyl)phenyl]methyl]-1-oxo-3,4-dihydroisoquinolin-6-yl]oxy]ethyl]-1-hydroxyurea 在 N-溴代丁二酰亚胺(NBS) 、 18-冠醚-6 、 dimethyl sulfide borane 、 potassium carbonate 、 三苯基膦 作用下， 以 四氢呋喃 、 丙酮 为溶剂， 反应 32.0h， 生成 1-{3-(4-Bromo-benzyloxy)-5-[2-(2-methyl-benzyloxy)-ethoxy]-benzyloxy}-5-bromomethyl-3-[3-(4-tert-butyl-benzyloxy)-5-(3-chloro-benzyloxymethyl)-benzyloxy]-2-iodo-benzene
  参考文献：
  名称：

  树突和树状聚合物中的序列

  摘要：

  各种官能团的顺序结合形成了生物大分子中特异性的基础。在人工大分子中引入这种多样性和测序能力从根本上是有趣的。在本文中，已使用三种不同的合成方法来构建树枝状聚合物和树枝状聚合物，其中所有单体单元互不相同。本文所述的合成策略涉及使用（i）ABB p单体，（ii）ABB'单体和（iii）ABB m单体。这些合成方法的互补性和多功能性应使其在各种应用中有用。

  DOI：

  10.1021/jo049878p
• 作为产物：
  描述：

  4-叔丁基苄溴 在 18-冠醚-6 、 dimethyl sulfide borane 、 sodium hydride 、 potassium carbonate 作用下， 以 四氢呋喃 为溶剂， 反应 17.0h， 生成 1-[2-[[2-[[4-(4-fluorophenyl)phenyl]methyl]-1-oxo-3,4-dihydroisoquinolin-6-yl]oxy]ethyl]-1-hydroxyurea
  参考文献：
  名称：

  树突和树状聚合物中的序列

  摘要：

  各种官能团的顺序结合形成了生物大分子中特异性的基础。在人工大分子中引入这种多样性和测序能力从根本上是有趣的。在本文中，已使用三种不同的合成方法来构建树枝状聚合物和树枝状聚合物，其中所有单体单元互不相同。本文所述的合成策略涉及使用（i）ABB p单体，（ii）ABB'单体和（iii）ABB m单体。这些合成方法的互补性和多功能性应使其在各种应用中有用。

  DOI：

  10.1021/jo049878p

文献信息

• Isoquinolyl substituted hydroxylamine derivatives
  申请人：Ciba-Geigy Corporation

  公开号：US05334600A1

  公开（公告）日：1994-08-02

  The compounds of the formula ##STR1## wherein R represents hydrogen, lower alkyl, aryl, biaryl, C.sub.3 -C.sub.7 -cycloalkyl, aryl-lower alkyl, aryl-lower alkenyl, aryl-lower alkynyl, aryloxy-lower alkyl, arylthio-lower alkyl, C.sub.3 -C.sub.7 -cycloalkyl-lower alkyl, biaryl-lower alkyl, aryl-C.sub.3 -C.sub.7 -cycloalkyl, aryl-C.sub.3 -C.sub.7 -cycloalkyl-lower alkyl or aryloxy-aryl-lower alkyl; and aryl represents carbocyclic or heterocyclic aryl; Z represents C.sub.1 -C.sub.3 -alkylene or vinylene, each unsubstituted or substituted by lower alkyl; Y represents SO.sub.2 (sulfonyl) or CO (carbonyl); A represents .sub.0 (oxygen), S (sulfur), or a direct bond; B represents lower alkylene; or B represents lower alkenylene or lower alkynylene provided that A represents a direct bond; X represents oxygen or sulfur, R.sub.1 represents hydrogen, acyl, lower alkoxycarbonyl, aminocarbonyl, mono- or di-lower alkylaminocarbonyl, lower alkenylaminocarbonyl, lower alkynylaminocarbonyl, carbocyclic or heterocyclic aryl-lower alkylaminocarbonyl, carbocyclic or heterocyclic arylaminocarbonyl, C.sub.3 -C.sub.7 -cycloalkylaminocarbonyl or C.sub.3 -C.sub.7 -cycloalkyl-lower alkylaminocarbonyl; R.sub.2 represents lower alkyl, lower alkoxycarbonyl-lower alkyl, C.sub.3 -C.sub.7 -cycloalkyl, carbocyclic or heterocyclic aryl, carbocyclic or heterocyclic aryl-lower alkyl, C.sub.3 -C.sub.7 -cycloaikyl-lower alkyl, amino, mono- or di-lower alkylamino, lower alkenylamino, lower alkynylamino, carbocyclic or heterocyclic aryl-lower alkylamino, carbocyclic or heterocyclic arylamino, C.sub.3 -C.sub.7 -cycloalkylamino, C.sub.3 -C.sub.7 -cycloalkyl-lower alkylamino or lower alkoxycarbonyl-lower alkylamino; R.sub.3 and R.sub.4 independently represent hydrogen or lower alkyl; R.sub.a represents hydrogen, lower alkyl, halo, trifluoromethyl or lower alkoxy; and pharmaceutically acceptable salts thereof; and their preparation and use as lipoxygenase inhibitors are described.

  该公式化合物的翻译如下：其中R代表氢、较低的烷基、芳基、联苯基、C.sub.3 -C.sub.7 -环烷基、芳基-较低烷基、芳基-较低烯基、芳基-较低炔基、芳氧基-较低烷基、芳硫基-较低烷基、C.sub.3 -C.sub.7 -环烷基-较低烷基、联苯基-较低烷基、芳基-C.sub.3 -C.sub.7 -环烷基、芳基-C.sub.3 -C.sub.7 -环烷基-较低烷基或芳氧基-芳基-较低烷基；芳基代表碳环芳基或杂环芳基；Z代表C.sub.1 -C.sub.3 -烷基或乙烯基，每个未被较低烷基取代；Y代表SO.sub.2（磺酰基）或CO（羰基）；A代表O（氧）、S（硫）或直接键；B代表较低烷基；或B代表较低烯基或较低炔基，前提是A代表直接键；X代表氧或硫；R.sub.1代表氢、酰基、较低烷氧羰基、氨基羰基、单-或双-较低烷基氨基羰基、较低烯基氨基羰基、较低炔基氨基羰基、碳环或杂环芳基-较低烷基氨基羰基、碳环或杂环芳基氨基羰基、C.sub.3 -C.sub.7 -环烷基氨基羰基或C.sub.3 -C.sub.7 -环烷基-较低烷基氨基羰基；R.sub.2代表较低烷基、较低烷氧羰基-较低烷基、C.sub.3 -C.sub.7 -环烷基、碳环或杂环芳基、碳环或杂环芳基-较低烷基、C.sub.3 -C.sub.7 -环烷基-较低烷基、氨基、单-或双-较低烷基氨基、较低烯基氨基、较低炔基氨基、碳环或杂环芳基-较低烷基氨基、碳环或杂环芳基氨基、C.sub.3 -C.sub.7 -环烷基氨基、C.sub.3 -C.sub.7 -环烷基-较低烷基氨基或较低烷氧羰基-较低烷基氨基；R.sub.3和R.sub.4独立地代表氢或较低烷基；R.sub.a代表氢、较低烷基、卤素、三氟甲基或较低烷氧基；以及其制备和用作脂氧酶抑制剂的药用盐。
• Indolyl substituted hydroxylamine derivatives
  申请人：Ciba-Geigy Corporation

  公开号：US05350761A1

  公开（公告）日：1994-09-27

  Disclosed are the compound of the formula ##STR1## wherein R represents hydrogen, lower alkyl, aryl, biaryl, C.sub.3 -C.sub.7 -cycloalkyl, aryl-lower alkyl, aryl-lower alkenyl, aryl-lower alkynyl, aryloxy-lower alkyl, arylthio-lower alkyl, C.sub.3 -C.sub.7 -cycloalkyl-lower alkyl, biaryl-lower alkyl, aryl-C.sub.3 -C.sub.7 -cycloalkyl, aryl-C.sub.3 -C.sub.7 -cycloalkyl-lower alkyl or aryloxy-aryl-lower alkyl; and aryl represents carbocyclic or heterocyclic aryl; Z represents C.sub.1 -C.sub.3 -alkylene or vinylene, each unsubstituted or substituted by lower alkyl; Y represents SO.sub.2 (sulfonyl) or CO (carbonyl); A represents O (oxygen), S (sulfur), or a direct bond; B represents lower alkylene; or B represents lower alkenylene provided that A represents a direct bond; X represents oxygen or sulfur, R.sub.1 represents hydrogen, acyl, lower alkoxycarbonyl, aminocarbonyl, mono- or di-lower alkylaminocarbonyl, lower alkenylaminocarbonyl, lower alkynylaminocarbonyl, carbocyclic or heterocyclic aryl-lower alkylaminocarbonyl, carbocyclic or heterocyclic arylaminocarbonyl, C.sub.3 -C.sub.7 -cycloalkylaminocarbonyl or C.sub.3 -C.sub.7 -cycloalkyl-lower alkylaminocarbonyl; R.sub.2 represents lower alkyl, lower alkoxycarbonyl-lower alkyl, C.sub.3 -C.sub.7 -cycloalkyl, carbocyclic or heterocyclic aryl, carbocyclic or heterocyclic aryl-lower alkyl, C.sub.3 -C.sub.7 -cycloalkyl-lower alkyl, amino, mono- or di-lower alkylamino, lower alkenylamino, lower alkynylamino, carbocyclic or heterocyclic aryl-lower alkylamino, carbocyclic or heterocyclic arylamino, C.sub.3 -C.sub.7 -cycloalkylamino, C.sub.3 -C.sub.7 -cycloalkyl-lower alkylamino or lower alkoxycarbonyl-lower alkylamino; R.sub.3 and R.sub.4 independently represent hydrogen or lower alkyl; R.sub.a represents hydrogen, lower alkyl, halo, trifluoromethyl or lower alkoxy; and pharmaceutically acceptable salts thereof; which are useful as lipoxygenase inhibitors.

  公开了式为##STR1##的化合物，其中R代表氢，低级烷基，芳基，双芳基，C.sub.3-C.sub.7-环烷基，芳基-低级烷基，芳基-低烯基，芳基-低炔基，芳氧基-低级烷基，芳硫基-低级烷基，C.sub.3-C.sub.7-环烷基-低级烷基，双芳基-低级烷基，芳基-C.sub.3-C.sub.7-环烷基，芳基-C.sub.3-C.sub.7-环烷基-低级烷基或芳氧基-芳基-低级烷基；芳基代表碳环芳基或杂环芳基；Z代表C.sub.1-C.sub.3-烷基或乙烯基，每个未取代或取代为低级烷基；Y代表SO.sub.2（磺酰基）或CO（羰基）；A代表O（氧）、S（硫）或直接键；B代表低级烷基；或B代表低烯基，前提是A代表直接键；X代表氧或硫，R.sub.1代表氢，酰基，低级烷氧羰基，氨基羰基，单或双低级烷基氨基羰基，低烯基氨基羰基，低炔基氨基羰基，碳环芳基或杂环芳基-低级烷基氨基羰基，碳环芳基或杂环芳基氨基羰基，C.sub.3-C.sub.7-环烷基氨基羰基或C.sub.3-C.sub.7-环烷基-低级烷基氨基羰基；R.sub.2代表低级烷基，低级烷氧羰基-低级烷基，C.sub.3-C.sub.7-环烷基，碳环芳基或杂环芳基，碳环芳基或杂环芳基-低级烷基，C.sub.3-C.sub.7-环烷基-低级烷基，氨基，单或双低级烷基氨基，低烯基氨基，低炔基氨基，碳环芳基或杂环芳基-低级烷基氨基，碳环芳基或杂环芳基氨基，C.sub.3-C.sub.7-环烷基氨基，C.sub.3-C.sub.7-环烷基-低级烷基氨基或低级烷氧羰基-低级烷基氨基；R.sub.3和R.sub.4独立地代表氢或低级烷基；R.sub.a代表氢，低级烷基，卤素，三氟甲基或低烷氧基；以及其药学上可接受的盐；它们可用作脂氧合酶抑制剂。
• Heteroaryl substituted hydroxylamine derivatives as lipoxygenase inhibitors
  申请人：CIBA-GEIGY AG

  公开号：EP0526402A1

  公开（公告）日：1993-02-03

  Disclosed are the compound of the formula wherein    R represents hydrogen, lower alkyl, aryl, biaryl, C₃-C₇-cycloalkyl, aryl-lower alkyl, aryl-lower alkenyl, aryl-lower alkynyl, aryloxy-lower alkyl, arylthio-lower alkyl, C₃-C₇-cycloalkyl-lower alkyl, biaryl-lower alkyl, aryl-C₃-C₇-cycloalkyl, aryl-C₃-C₇-cycloalkyl-lower alkyl or aryloxy-aryl-lower alkyl; and aryl represents carbocyclic or heterocyclic aryl;    Z represents C₁-C₃-alkylene or vinylene, each unsubstituted or substituted by lower alkyl;    Y represents SO₂ (sulfonyl) or CO (carbonyl);    A represents O (oxygen), S (sulfur), or a direct bond;    B represents lower alkylene; or B represents lower alkenylene provided that A represents a direct bond;    X represents oxygen or sulfur,    R₁ represents hydrogen, acyl, lower alkoxycarbonyl, aminocarbonyl, mono- or di-lower alkylaminocarbonyl, lower alkenylaminocarbonyl, lower alkynylaminocarbonyl, carbocyclic or heterocyclic aryl-lower alkylaminocarbonyl, carbocyclic or heterocyclic arylaminocarbonyl, C₃-C₇-cycloalkylaminocarbonyl or C₃-C₇-cycloalkyl-lower alkylaminocarbonyl;    R₂ represents lower alkyl, lower alkoxycarbonyl-lower alkyl, C₃-C₇-cycloalkyl, carbocyclic or heterocyclic aryl, carbocyclic or heterocyclic aryl-lower alkyl, C₃-C₇-cycloalkyl-lower alkyl, amino, mono- or di-lower alkylamino, lower alkenylamino, lower alkynylamino, carbocyclic or heterocyclic aryl-lower alkylamino, carbocyclic or heterocyclic arylamino, C₃-C₇-cycloalkylamino, C₃-C₇-cycloalkyl-lower alkylamino or lower alkoxycarbonyl-lower alkylamino;    R₃ and R₄ independently represent hydrogen or lower alkyl;    Ra represents hydrogen, lower alkyl, halo, trifluoromethyl or lower alkoxy; and pharmaceutically acceptable salts thereof; which are useful as lipoxygenase inhibitors.

  公开了式中的化合物 其中 R 代表氢、低级烷基、芳基、双芳基、C₃-C₇-环烷基、芳基-低级烷基、芳基-低级烯基、芳基-低级炔基、芳氧基-低级烷基、芳硫基-低级烷基、C₃-C₇-环烷基-低级烷基、双芳基-低级烷基、芳基-C₃-C₇-环烷基、芳基-C₃-C₇-环烷基-低级烷基或芳氧基-芳基-低级烷基；芳基代表碳环芳基或杂环芳基； Z 代表 C₁-C₃-亚烷基或乙烯基，各自未被低级烷基取代或被低级烷基取代； Y 代表 SO₂（磺酰基）或 CO（羰基）； A 代表 O（氧）、S（硫）或直接键； B 代表低级亚烷基；或 B 代表低级烯基，条件是 A 代表直接键； X 代表氧或硫、 R₁ 代表氢、酰基、低级烷氧基羰基、氨基羰基、单-或双-低级烷基氨基羰基、低级烯基氨基羰基、低级炔基氨基羰基、碳环或杂环芳基-低级烷基氨基羰基、碳环或杂环芳基氨基羰基、C₃-C₇-环烷基氨基羰基或 C₃-C₇-环烷基-低级烷基氨基羰基； R₂ 代表低级烷基、低级烷氧基羰基-低级烷基、C₃-C₇-环烷基、碳环或杂环芳基、碳环或杂环芳基-低级烷基、C₃-C₇-环烷基-低级烷基、氨基、单-或双-低级烷基氨基、低级烯基氨基、低级炔基氨基、碳环或杂环芳基-低级烷基氨基、碳环或杂环芳基氨基、C₃-C₇-环烷基氨基、C₃-C₇-环烷基-低级烷基氨基或低级烷氧基羰基-低级烷基氨基； R₃ 和 R₄ 各自代表氢或低级烷基； Ra代表氢、低级烷基、卤代、三氟甲基或低级烷氧基；及其药学上可接受的盐；它们可用作脂氧合酶抑制剂。
• Controlled release drug delivery device
  申请人：Novartis AG

  公开号：EP0621032B1

  公开（公告）日：2000-08-09
• Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas
  申请人：Claesson Hans-Erik

  公开号：US20080081835A1

  公开（公告）日：2008-04-03

  The invention relates to the use of an inhibitor of the biosynthesis and/or function of LTB 4 for the manufacture of a medicament for the treatment of B-cell chronic lymphocytic leukemia (B-CLL), B-prolymphocytic leukemia (B-PLL) or B-cell lymphoma. Preferably, the inhibitor of the biosynthesis and/or function of LTB 4 is the inhibitor of 5-LO BWA4C or the inhibitor of FLAP MK-886.